Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02983305 · ClinicalTrials.gov registry record · NA

Optical Head-Mounted Display Technology for Low Vision Rehabilitation

A NA study of Healthy and Retinal Dystrophies, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT02983305: Completed NA study of Healthy and Retinal Dystrophies, sponsored by University of Michigan.

NCT02983305 is a NA study of Healthy and Retinal Dystrophies that has completed, run by University of Michigan. The registered enrollment target is 22 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02983305, a NA study of Healthy and Retinal Dystrophies, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to examine the ability of optical head-mounted display technology to enlarge the visual field of patients with severe visual field loss due to retinal dystrophy and to improve mobility and patient-reported outcomes.

Primary Outcome

Using computer software we will calculate the area of participants' Goldmann visual fields in order to obtain a summary quantitative measurement of the extent of peripheral vision. Average of both eyes visual fields with intervention.

Interventions

  • DEVICE Head-Mounted Display

Study Locations (1)

Michigan

  • Kellogg Eye Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2017-06-26
Est. Completion 2018-11-21
Phase NA
University of Michigan

1,327 total trials

What the finished NCT02983305 record still lists

NCT02983305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Head-Mounted Display is the first listed.

NCT02983305 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT02983305 about?

NCT02983305 is a clinical study titled "Optical Head-Mounted Display Technology for Low Vision Rehabilitation". The goal of this study is to examine the ability of optical head-mounted display technology to enlarge the visual field of patients with severe visual field loss due to retinal dystrophy and to improve mobility and patient-reported outcomes.

What is the current status of trial NCT02983305?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2017-06-26. Estimated completion is 2018-11-21.

What conditions does trial NCT02983305 study?

This clinical trial studies the following conditions: Healthy, Retinal Dystrophies.

What interventions are being tested in trial NCT02983305?

The interventions under investigation include: Head-Mounted Display (DEVICE).

Who is sponsoring clinical trial NCT02983305?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02983305 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02983305's enrollment target sits among peer trials

22 844th of 1090 higher than 235 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02983305, the US trial registry maintained by the National Library of Medicine. NCT02983305 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.